[en] BACKGROUND AND AIM: Ulcerative proctitis affects approximately 30% of patients with ulcerative colitis. Disease control is essential to maintain quality of life and to prevent disability and disease progression. The aim of this study was to investigate current practice on isolated proctitis management across the globe. METHODS: Physicians with experience in treating inflammatory bowel diseases (IBD) were invited to participate in an anonymous, multiple-choice survey between January and February 2025. RESULTS: The survey included 460 physicians from 66 countries. Most participants (87.9%) assessed clinical activity of isolated proctitis within 3 months of treatment initiation, 75.9% used fecal calprotectin, and 67.1% used C-reactive protein to measure disease activity. Endoscopic assessment was performed 3 to 6 months (34.2%) or 6 to 12 months (48.4%) after treatment induction. In this survey, 49% of participants were more reluctant to begin an advanced therapy in patients with isolated proctitis compared to pancolitis or left-sided colitis. About two-thirds of participants were less likely to use biologics in combination with immunosuppressants in isolated proctitis compared to left-sided or pancolitis. Anti-TNF (tumor necrosis factor) was the preferred choice in first-line advanced therapy after failing conventional treatment (48.4%). CONCLUSION: This study highlighted differences in management of isolated proctitis compared to left-sided colitis or pancolitis. This is likely explained by the fact that isolated proctitis patients were historically excluded from clinical trials; therefore, management relied on extrapolation of data from studies on more extensive disease.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Caron, Bénédicte; Department of Gastroenterology, Nancy University Hospital, and INSERM, NGERE, University of Lorraine, 54000, Nancy, France.
Sequier, Léa; Department of Gastroenterology and Hepatology, Nîmes University Hospital, Carémeau Hospital, Nîmes, France.
Dignass, Axel; Department of Medicine I, Goethe University, Agaplesion Markus Hospital, Frankfurt, Germany.
Ghosh, Subrata; Department of Medicine, University College Cork, Cork, Ireland.
Hart, Ailsa; IBD Unit, St. Mark's Hospital, London, UK.
Jairath, Vipul; Alimentiv, London, ON, Canada. ; Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada. ; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Kobayashi, Taku; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Kotze, Paulo Gustavo; Health Sciences Postgraduate Program (PPGCS), IBD Outpatient Clinics, Pontifícia Universidade Católica Do Paraná (PUCPR), Curitiba, Brazil.
Lakatos, Peter L; Division of Gastroenterology, McGill University, Montreal, QC, H3G1A4, Canada. ; Department of Internal Medicine and Oncology, Semmelweis University, Budapest, 1085, Hungary.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Magro, Fernando; Faculty of Medicine, CINTESIS@RISE, University of Porto, Porto, Portugal.
Sebastian, Shaji; IBD Unit, Hull University Teaching Hospitals, Hull, UK.
Solitano, Virginia; Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy. ; Università Vita-Salute San Raffaele, Milan, Italy. ; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
Sidhu, Sarah; Pfizer Inc, New York, NY, USA.
Danese, Silvio; Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Milan, Italy. ; Department of Immunology, Transplantation and Infectious Disease, Università Vita-Salute San Raffaele, Milan, Italy.
Peyrin-Biroulet, Laurent; Department of Gastroenterology, Nancy University Hospital, and INSERM, NGERE, University of Lorraine, 54000, Nancy, France. peyrinbiroulet@gmail.com. ; INSERM NGERE U1256 and Department of Gastroenterology, Nancy University Hospital, University of Lorraine, 1 Allée du Morvan, 54511, Vandoeuvre-lès-Nancy, France. peyrinbiroulet@gmail.com.
A. Hochart C. Gower-Rousseau H. Sarter et al. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study Gut 66 1912 1917 1:STN:280:DC%2BC2s3nsVKjtQ%3D%3D 10.1136/gutjnl-2016-311970 27489240
J.M. Huguet L. Ferrer-Barceló P. Suárez et al. Endoscopic progression of ulcerative proctitis to proximal disease. Can we identify predictors of progression? Scand J Gastroenterol 53 1286 1290 10.1080/00365521.2018.1524026 30351984
B. Caron W.J. Sandborn R. Panaccione et al. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review J Crohns Colitis 10.1093/ecco-jcc/jjab218 33550374
E. Dubois A. Moens R. Geelen J. Sabino M. Ferrante S. Vermeire Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort United Eur Gastroenterol J. 8 933 941 10.1177/2050640620941345
B. Caron W.J. Sandborn S. Schreiber R. Panaccione S. Danese L. Peyrin-Biroulet Drug development for ulcerative proctitis: current concepts Gut. 70 1203 1209 10.1136/gutjnl-2021-324108 33789968
G. Pineton de Chambrun A. Amiot G. Bouguen et al. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis Clin Gastroenterol Hepatol. 18 620 627 1:CAS:528:DC%2BC1MXhtlOgsbfE 10.1016/j.cgh.2019.05.060 31202984
A.L. Mallet G. Bouguen G. Conroy et al. Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 49 280 285 1:CAS:528:DC%2BC28XitVyltLvP 10.1016/j.dld.2016.12.001
G. Bouguen X. Roblin A. Bourreille et al. Infliximab for refractory ulcerative proctitis Aliment Pharmacol Ther. 31 1178 1185 1:CAS:528:DC%2BC3cXnsl2gsLg%3D 10.1111/j.1365-2036.2010.04293.x 20222911
W.J. Sandborn S. Vermeire L. Peyrin-Biroulet et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies Lancet Lond Engl. 401 1159 1171 10.1016/S0140-6736(23)00061-2
L. Peyrin-Biroulet M.C. Dubinsky B.E. Sands et al. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme J Crohns Colitis. 18 1270 1282 10.1093/ecco-jcc/jjae038 38613425 11324338
B.E. Sands R. Panaccione G. D’Haens et al. Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial Lancet Gastroenterol Hepatol. 10 210 221 1:CAS:528:DC%2BB2MXotFemuw%3D%3D 10.1016/S2468-1253(24)00386-8 39793589
B. Caron M.T. Abreu C.A. Siegel et al. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 10.1016/j.cgh.2022.02.032
J.A. Sninsky E.L. Barnes X. Zhang M.D. Long Urgency and Its Association With Quality of Life and Clinical Outcomes in Patients With Ulcerative Colitis Am J Gastroenterol. 117 769 776 1:CAS:528:DC%2BB3sXnsFejs7k%3D 10.14309/ajg.0000000000001685 35169109 9064909
B. Caron S. Ghosh S. Danese L. Peyrin-Biroulet Identifying, Understanding, and Managing Fecal Urgency in Inflammatory Bowel Diseases Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 21 1403 1413.e27 10.1016/j.cgh.2023.02.029
Steinsbø Ø, Aasprong OG, Aabakken L, Karlsen LN, Grimstad T. 2025. Fecal Calprotectin Correlates with Disease Extent but Remains a Reliable Marker of Mucosal Healing in Ulcerative Colitis. Am J Gastroenterol https://doi.org/10.14309/ajg.0000000000003339
E.Y. Liu A. An S. Khan et al. The Impact of Endoscopic Healing on Disease-Related Outcomes in Patients With Ulcerative Proctitis Inflamm Bowel Dis 10.1093/ibd/izaf044 41173046 12558586
T. Raine S. Bonovas J. Burisch et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment J Crohns Colitis. 16 2 17 10.1093/ecco-jcc/jjab178 34635919
S. Singh E.V. Loftus B.N. Limketkai et al. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Gastroenterology. 167 1307 1343 1:CAS:528:DC%2BB2cXisFOltrrE 10.1053/j.gastro.2024.10.001 39572132
R.G. Farmer K.A. Easley G.B. Rankin Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients Dig Dis Sci 38 1137 1146 1:STN:280:DyaK3s3osV2kug%3D%3D 10.1007/BF01295733 8508710
A. Miyazawa R. Nambu H. Shimizu et al. Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis A Multicenter Cohort Study Inflamm Bowel Dis 10.1093/ibd/izae266 38588461 12235130
R. Ferreiro-Iglesias S. Porto Silva S. Marín et al. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry Aliment Pharmacol Ther. 60 604 612 1:CAS:528:DC%2BB2cXhsFSms7%2FI 10.1111/apt.18133 38943230
D. De Deo A. Dal Buono R. Gabbiadini et al. Management of proctitis in ulcerative colitis and the place of biological therapies Expert Opin Biol Ther. 24 443 453 10.1080/14712598.2024.2369189 38874980
P. Lemmens E. Louis W. Van Moerkercke et al. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study Clin Gastroenterol Hepatol. 22 154 163.e3 1:CAS:528:DC%2BB3sXhs12gtr3I 10.1016/j.cgh.2023.06.023 37442318
R.S. Dalal L.M. Clarke A. Carlin H. Cabral J.R. Allegretti Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis Inflamm Bowel Dis. 31 1174 1177 10.1093/ibd/izae215 39301678
A.W. Nguyen A.R. Srinivasan M. Lai T. Schildkraut A. Vasudevan Inclusion of patients with isolated ulcerative proctitis in clinical trials Lancet Gastroenterol Hepatol. 10 504 1:CAS:528:DC%2BB2MXhtVKlu7vL 10.1016/S2468-1253(25)00108-6 40347955
